Interferon alfa-2b: Difference between revisions
No edit summary |
|||
| Line 33: | Line 33: | ||
==Mechanism of Action== | ==Mechanism of Action== | ||
The mechanism by which INTRON A may alter thyroid status is unknown. The mechanism by which these events developed and their relationship to interferon alpha therapy is not clear. | |||
==References== | ==References== | ||
Revision as of 20:26, 8 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Interferon alfa-2b is an antiviral drug discovered and marketed by Schering-Plough under the tradename Intron-
®. It has been used for a wide range of indications, including viral infections and cancers. This drug is approved around the world for the treatment of chronic hepatitis C, chronic hepatitis B, hairy cell leukemia, chronic myelogenous leukemia, multiple myeloma, follicular lymphoma, carcinoid tumor, and malignant melanoma.
Category
Antiviral
US Brand Names
INTRON A®
FDA Package Insert
Description | Clinical Pharmacology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Overdosage | Dosage and Administration | How Supplied | Labels and Packages
Mechanism of Action
The mechanism by which INTRON A may alter thyroid status is unknown. The mechanism by which these events developed and their relationship to interferon alpha therapy is not clear.